Schizophrenia biomarkers found by GeneNews’ Sentinel Principle

A study using GeneNews’ (TSX:GEN) Sentinel Principle platform technology to identify complex changes in blood gene expression patterns that may be indicative of underlying risk factors for schizophrenia will be published in the American Journal of Medical Genetics Part B and is currently available online. “This study shows that we can identify a gene signature [...]

GeneNews technology able to predict risk of liver cancer for patients with chronic hepatitis

A poster entitled “Biomarkers to predict risk of subsequent hepatocellular cancer in patients with chronic hepatitis,” describing the initial phase of analysis of a 1,600-cohort study using GeneNews’ (TSX:GEN) Sentinel Principle, was presented at the 9th Liver Update 2011 conference in Malaysia. The poster reports on the application of the Sentinel Principle platform technology to [...]

GeneNews closes warrant exercise incentive program

GeneNews (TSX:GEN) has completed an early warrant exercise incentive program and debenture conversion, raising almost $3 million. A total of 74% of eligible warrants were exercised and the company issued 12.8 million common shares and 12.8 million incentive warrants. In addition, holders of 25% of eligible convertible debentures participated in the debenture conversion, resulting in [...]

GeneNews holders okay early warrant campaign

Shareholders of GeneNews (TSX:GEN) at the annual meeting approved an early warrant exercise incentive program to run from May 17 to June 8. If all warrants eligible to participate in the program are exercised during the 22-day period, the company expects it will receive gross proceeds of up to about $4.1-million, and issue up to [...]

Personalized medicine is more than targeted therapeutics

That’s a message Enzo Biochem (NYSE:ENZ) wants to get out. “We are positioned extremely well for personalized medicine in the sense that as new immunoassays are recommended by the various professional societies, we are able to move them into the market very quickly because of our broad range of technology and licensure,” David Goldberg, VP [...]

Enzo backs utility of GeneNews test

In an interview with partneringNews, Kevin Krenitsky, President of Enzo Clinical Labs, a unit of Enzo Biochem (NYSE:ENZ), called GeneNews’ (TSX:GEN) ColonSentry pre-screening assay for colorectal cancer risk assessment a “benchmark example for the types of tests Enzo will be advancing.” GeneNews previously licensed ColonSentry to Enzo, which submitted the test for approval to New York [...]

Enzo gets positive feedback from GeneNews test

Rodman & Renshaw, in a new report that cites an Enzo Biochem (NYSE:ENZ) conference call, says that Enzo has initiated early marketing research and a roll-out strategy to assess interest among physicians and patients of GeneNews’ (TSX:GEN) ColonSentry test, “with a strong positive response for the new test.” GeneNews previously licensed ColonSentry to Enzo, which [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

GeneNews partner submits data to NY

Enzo Clinical Labs (NYSE: ENZ) has submitted a validation data package for GeneNews’ (TSX:GEN) ColonSentry test to New York State health regulatory authorities. “Offering first-in-class tests such as ColonSentry is a central component of Enzo’s strategy of bringing leading edge, world-class molecular tests to our customers,” Enzo Clinical Labs’ president Dr. Kevin Krenitsky said in [...]

GeneNews raises $2.1 Million

GeneNews (TSX: GEN) has accepted subscription agreements with a number of investors for two concurrent private placement offerings of units and convertible debentures to raise gross proceeds of $2,125,452, with insiders subscribing for about 49%. Each unit consists of one common share, one-half of a Series A warrant and one-half of a Series B warrant. [...]

« Previous Page — Next Page »